Immunotech Biopharm reports wider loss despite EAL® NDA progress

Immunotech Biopharm Ltd. reported a loss before tax of RMB129,030,000 for the six months ended June 30, 2025, a 39.4% increase from RMB92,556,000 in the same period of 2024. The net loss attributable to owners was RMB129,103,000, resulting in a basic and diluted loss per share of RMB0.25. Other income rose by 99.8% to RMB13,036,000, primarily due to an increase in government grants. However, net other losses reached RMB51,045,000, a turnaround from gains in the prior period, mainly due to fair value loss on other financial liabilities.

Cash and bank balances decreased to RMB21,053,000 as of June 30, 2025, from RMB47,000,000 at December 31, 2024. Net current liabilities increased to RMB455,776,000 from RMB342,712,000, and net liabilities grew to RMB145,485,000 from RMB16,453,000. Research and development expenses decreased by 26.0% to RMB67,449,000.

The company made progress on its core product candidate, EAL®, with the conditional New Drug Application (NDA) under review by the CDE of the NMPA as of the reporting date. The group utilized RMB300,000,000 from convertible bonds proceeds by June 30, 2025, allocating funds for EAL® clinical trials and the construction of new R&D and production centers.